Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Universitario Ramon y Cajal | OTHER |
| Hospital Universitari Vall d'Hebron Research Institute | OTHER |
| Institut Català d'Oncologia | OTHER |
Not provided
Not provided
Not provided
This study is an open-label,non randomized, multi-center, phase 1/2b (dose escalation followed by expansion part) study evaluating clinical safety, efficacy and pharmacokinetics of PQR309 in combination with standard dose of eribulin in patients with locally advanced or metastatic HER2-negative (escalation part) and Triple Negative Breast Cancer (expansion part).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eribulin and PQR309 | Experimental | PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PQR309 | Drug | Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with treatment related Adverse Events and Serious Adverse Events as assessed by NCI CTCAEV4.03 | Continous dosing and intermittent schedules of PQR309 | Up to 6 months |
| RECIST the Response criteria for solid tumors will be used to identify clinical benefit rate (CBR) including complete Response (CR), partial Response (PR) and stable disease (SD) | Continous dosing and intermittent schedules of PQR309 | Up to 15 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with Adverse Events and Serious Adverse Events and number of anormal laboratory values that constitute an Adverse Events on their own | Continous dosing and intermittent schedules of PQR309 | Up to 12 months |
| Number and percent of patients having each ECOG (Eastern Oncology Cooperative Group) performance status level will be presented for baseline and each post-baseline measurement. |
Not provided
Inclusion Criteria:
Triple-negative breast cancer defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0,1+ or 2+ER abnd PR status <10% by local laboratory testing.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Javier Cortes, PD Dr. med | Hospital Universitario Ramon y Cajal | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitarsi Vall d'Hebron | Barcelona | Catalan | 08035 | Spain | ||
| Insitut Català d´Oncologia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C490954 | eribulin |
Not provided
Not provided
Not provided
| Churchill Hospital |
| OTHER |
| Barts Cancer Institute | OTHER |
| Fundación Instituto Valenciano de Oncología | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Eribulin | Drug | non.taxane microtubule dynamics inhibitor |
|
|
Continous dosing and intermittent schedules of PQR309 |
| up to 12 months |
| Assessment of PQR309 and Eribulin blood concentration | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Physical examination, Body weight in kg | Continous dosing and intermittent schedules | up to 12 months |
| Physical examination, ECG | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Vital signs like heart rate | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Vital signs like blood pressure | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Vital signs like body temperature | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Objective Response Rate (ORR), is defined as the best overall response (confirmed CR or PR) recorded for each patient since baseline. | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Time to Response (TTR) is defined, for patients with tumor response, as the time from the date of study entry to the first documentation of response (complete or partial) | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Duration of response (DOR) is defined, for the patients with tumor response, as the time from the date of the first confirmed response to disease progression. | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Progression- free survival (PFS) is defined as the time from study entry to progression or death due to any cause | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Time to treatment failure (TTF) is defined as the time from study entry to any treatment failure including disease progression or discontinuation of treatment | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| 1-year survival, defined as the time from study entry to death as a result of any cause at 1-year cut-off date | Continous dosing and intermittent schedules of PQR309 | up to 12 months |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax | Intermittent schedule B: "Monday/ Thursday" | On Cycle 1 Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion and on Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax | Intermittent schedule B: "Monday/ Thursday" | On Cycle 1 Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion and on Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24 | Intermittent schedule B: "Monday/ Thursday" | On Cycle 1 Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion and on Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-∞ | Intermittent schedule B: "Monday/ Thursday" | On Cycle 1 Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion and on Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC(Racemate) | Intermittent schedule B: "Monday/ Thursday" | On Cycle 1 Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion and on Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax | Intermittent schedule A: 2 days on/5 days off | PK is being assessed during Cycle 1 on Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion. On Cycle 1 Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose. |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax | Intermittent schedule A: 2 days on/5 days off | PK is being assessed during Cycle 1 on Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion. On Cycle 1 Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose. |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24 | Intermittent schedule A: 2 days on/5 days off | PK is being assessed during Cycle 1 on Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion. On Cycle 1 Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose. |
| PK parameters of PQR309 and eribulin will include: AUC0-∞ | Intermittent schedule A: 2 days on/5 days off | PK is being assessed during Cycle 1 on Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion. On Cycle 1 Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose. |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC | Intermittent schedule A: 2 days on/5 days off | PK is being assessed during Cycle 1 on Day 8: pre-dose, end of eribulin infusion, 2h and 6h post end of eribulin infusion. On Cycle 1 Day 15: pre-dose and one sample between 1 and 3 hours post PQR309 dose. |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax | Continous Dosing | It will be measured pre-dose and at the end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end and at end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end of eribulin during Cycle 1 on day 1 and 8 and beyond cycle 1 on day 1 |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24 | Continous Dosing | It will be measured pre-dose and at the end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end and at end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end of eribulin during Cycle 1 on day 1 and 8 and beyond cycle 1 on day 1 |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-∞ | Continous Dosing | It will be measured pre-dose and at the end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end and at end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end of eribulin during Cycle 1 day on 1 and 8 and beyond cycle 1 on day 1 |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: t1/2 | Continous Dosing | It will be measured pre-dose and at the end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end and at end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end of eribulin during Cycle 1 on day 1 and 8 and beyond cycle 1 on day 1 |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax | Continous Dosing | It will be measured pre-dose and at the end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end and at end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end of eribulin during Cycle 1 on day 1 and 8 and beyond cycle 1 on day 1 |
| Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC (Racemate) | Continous Dosing | It will be measured pre-dose and at the end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end and at end of eribulin infusion and 0.5h, 1h, 2h, 4h, and 8h post end of eribulin during Cycle 1 on day 1 and 8 and beyond cycle 1 on day 1 |
| Changes in glucose levels | Continous dosing and intermittent schedules of PQR309 | 12 months |
| Changes in Insulin levels | Continous dosing and intermittent schedules of PQR309 | 12 months |
| Changes of Routine laboratory -Haematology | Continous dosing and intermittent schedules of PQR309 | 12 months |
| Changes of Routine laboratory -blood chemistry | Continous dosing and intermittent schedules of PQR309 | 12 months |
| Changes of Routine laboratory -urinanalysis | Continous dosing and intermittent schedules of PQR309 | 12 months |
| Barcelona |
| Spain |
| Fundación Instituto Valenciano de Oncología | Valencia | Spain |
| Barts Cancer Institute | London | United Kingdom |
| Churchill hospital | Oxford | United Kingdom |
| D017437 |
| Skin and Connective Tissue Diseases |